Human medicines European public assessment report (EPAR): Lutathera, lutetium (177Lu) oxodotreotide, Date of authorisation: 26/09/2017, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): MabThera, rituximab, Date of authorisation: 02/06/1998, Revision: 63, Status: Authorised

Antimicrobial Sales and Use (ASU) Platform: Release notes

Human medicines European public assessment report (EPAR): Jinarc, tolvaptan, Date of authorisation: 27/05/2015, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Seffalair Spiromax, salmeterol,fluticasone propionate, Date of authorisation: 26/03/2021, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): ellaOne, ulipristal acetate, Date of authorisation: 15/05/2009, Revision: 35, Status: Authorised

Human medicines European public assessment report (EPAR): Camcevi, leuprorelin, Date of authorisation: 24/05/2022, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Tukysa, tucatinib, Date of authorisation: 11/02/2021, Revision: 9, Status: Authorised

Reflection paper on use of real-world data in non-interventional studies to generate real-world evidence for regulatory purposes

Journey towards a roadmap for regulatory guidance on real-world evidence